NCT02139267已完成2 期
A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 8
- 主要终点
- The Rate of Participants with Histopathological Regression of Cervical Lesions to CIN1 or Less
研究概览
简要总结
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
详细描述
Subjects who are eligible for this study are allocated to one of the two treatment groups of GX-188E. All Subject received GX-188E intramuscularly using the electroporator(EP) on alternating deltoid muscles which will be performed totally three times during the study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntarily signed informed consent form after receiving education about this study and the investigational product.
- •Female aged between 19 and 50 years
- •Positive test results for HPV Type 16 and/or Type 18
- •Histopathologically-confirmed Cervical Intraepithelial Neoplasia 3
- •Entire cervical area including entire squamocolumnar junction is visualized through colposcopy
- •Eligible based on screening test results.
- •Promised not to get pregnant throughout the study
排除标准
- •Suspected Adenocarcinoma in situ
- •Malignant cancer more than Stage I
- •Pregnancy or breastfeeding
- •Participation in clinical trials within 30 days of the screening visit
- •Administration of immunosuppressant or immunomodulator within 6 months prior to the enrolment
- •Administered with systemic steroid(as a standard with Prednisolone, more than 20mg/day for every 14 days or more) within 3 months of Day 1(including ointment, eye drops, inhalated or nasal, intra-ligamental or intra-articular injection, but not applicable if injected every other day
- •Administered any blood products within 3 months prior to the screening visit
- •Administered any vaccine within 4 weeks prior to the screening visit(ex. Hepatitis A, Hepatitis B, Influenza, Td etc.)
- •Positive serum test results for hepatitis C virus, hepatitis B virus surface antigen(HBsAg) or HIV
- •Severe hepatopathy which is Class C according to Child-Pough's classification
- •Severe renal dysfunction where the creatinine clearance(CLcr) is lower than 30ml/min
- •CPK test results more than 2.5 times the upper limit of normal
- •Predisposed to inflammatory reaction due to use of medical devices such as electroporation within 30 days of screening visit
- •History of severe adverse drug events or severe allergic diseases
- •History of epilepsy or convulsion within 2 years prior to the screening visit
- •At the discretion of the investigator, the skin condition covering deltoid muscles, within 2cm of the intended sites of injection, is not suitable for injection due to infection, ulcer, edema, tattoo, scar, injury etc.
- •The thickness of skin fold covering deltoid muscles, intended injection sites, > 40mm
- •Any orthopedic artificial implant around the intended sites of electroporation (deltoid muscles)
- •Sinus bradycardia whose resting heart rate < 50 beats/min
- •Pre-excitation syndrome such as Wolff-Parkinson-White syndrome
- •Abnormal electrocardiography(ECG) including arrhythmia
- •Artificial implants or metallic implants
- •Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
研究组 & 干预措施
1mg of GX-188E per dose
Experimental
1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
干预措施: GX-188E (Biological)
4mg of GX-188E per dose
Experimental
4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
干预措施: GX-188E (Biological)
结局指标
主要结局
The Rate of Participants with Histopathological Regression of Cervical Lesions to CIN1 or Less
时间窗: 20 weeks
次要结局
- The Rate of Adverse Events and the Related Features after Administration of Investigational Product(20 weeks)
- The Rate of Solicited Adverse Events and the Related Features(20 weeks)
- Data in Physical examination, Vital signs, Electrocardiography, Clinical Laboratory Test Results Related to Investigational Product(20 weeks)
- Mean Value of Visual Analogue Scale on Pain Intensity(20 weeks)
- Flt-3L Serum Concentration(20 weeks)
- The Rate of Participants Whose Result Inverted Negative in HPV DNA test(20 weeks)
- The rate of HPV E6, E7-specific ELISPOT responder defined in the protocol(20 weeks)
- Cytological Changes of the Cervical Lesions(20 weeks)
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
2 期
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)Cervical Intraepithelial NeoplasiaNCT02596243Genexine, Inc.134
已完成
2 期
Study of GSK1363089 in Metastatic Gastric CancerNeoplasms, Gastrointestinal TractNCT00725712GlaxoSmithKline74
进行中（未招募）
2 期
GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT06566547Genrix (Shanghai) Biopharmaceutical Co., Ltd.116
已完成
1 期
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaStage IV MelanomaStage III MelanomaNCT02676869Immutep Australia Pty. Ltd.24
招募中
2 期
Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic NeuropathyLeber's Hereditary Optic Neuropathy (LHON)NCT04912843Wuhan Neurophth Biotechnology Limited Company102